• Drug utilization studies (DUS) are increasingly requested by health authorities and payers to evaluate the benefit-risk of drugs in the realworld clinical practice setting.
The lack of consensus in the legislative and ethical framework for DUS across different Latin American countries leads to operational challenges for the implementation of cross-national drug utilization studies. 
METHODS

CONCLUSION RESULTS
Survey
• Great disparity across local legislations on DUS in Latin America.
• Heterogeneous ethical requirements at the level of institutions and variation in the data protection legislation.
• Major differences arise for DUS involving ad hoc data collection (i.e., chart review or questionnaire to prescribers or patients).
• In most countries, DUS have to be notified to competent health authorities and/or regional ethics committees. However, depending on various elements such as the country, setting or data collection method, applicable ethical requirements for DUS might differ, as shown below.
DUS with medical chart review -Hospital setting
• Approval from a hospital ethics committee or IRB appears to be required in every country.
• Need for patient informed consent and/or contractual agreements depends on the country considered and the data collection method.
For example, in Brazil, hospital physicians can request an exemption of informed consent forms in a retrospective review of medical records.
DUS with medical chart review -Community care setting
• Similar requirements as for DUS conducted in the hospital setting.
• Approval from a data protection agency is not required for any investigated country.
• Need for a local or regional ethics committee approval.
For example, in Guatemala, type of setting, either public or private, determines whether a national or institutional ethics committee approval is needed.
DUS with patient survey
• Usually, approval from a local or regional ethics committee is required.
• Patient informed consent appears to be necessary in every country.
• Additional requirements related to personal data protection only apply to Argentina and Costa Rica.
DUS in the pediatric population
• Depending on the country considered, the patient or legal guardian informed consent is not always required for DUS involving only a medical chart review.
• In most countries, similar ethical requirements apply to this population as those for the adult population. • Most ethics committees refer to the Declaration of Helsinki and/or to national guidelines regarding the ethical requirements applicable for DUS (n=9; 69.2%).
• These reference documents are often used in combination. • Participation: Out of the 93 ethics committees and/or key informants contacted, 13 answered the survey (14% participation). 
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